SRSD 107
Alternative Names: SRSD-107Latest Information Update: 19 Feb 2024
At a glance
- Originator Sirius Therapeutics
- Class Antithrombotics; Small interfering RNA
- Mechanism of Action Factor XI expression inhibitors; RNA interference
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase I Thrombosis
Most Recent Events
- 23 Jan 2024 Phase-I clinical trials in Thrombosis (In volunteers) in Australia (SC) (NCT06116617)
- 10 Nov 2023 Sirius Therapeutics submitted application in Australia for Thrombosis to begin first-in-human clinical trial
- 03 Nov 2023 Sirius Therapeutics plans a phase I trial for Thrombosis (In volunteers) in Australia (SC, Injection), in January 2024 (NCT06116617)